Abstract: Objective To investigate the correlation of serum levels of sclerostin(SOST) and 25 hydroxyvitamin D[25(OH)D] with cognitive function in the patients with Alzheimer’s disease(AD). Methods A total of 30 patients with AD and 30 patients with mild cognitive impairment(MCI) treated in Xuzhou Central Hospital from January 2020 to December 2022, and 30 cases of age-, sex- and education-matched healthy controls during the same period were enrolled in this study. The serum levels of SOST and 25(OH)D in the three groups were detected and compared, and the correlation between serum levels of SOST, 25(OH)D and the score of mini-mental state examination(MMSE) in AD group was analyzed. Results The serum SOST level was significantly higher, and the serum 25(OH)D level was significantly lower in AD group than that in healthy control group(P<0.01). There were no significant differences in serum SOST and 25(OH)D levels between MCI group and healthy control group(all P> 0.05).Serum SOST level was negatively correlated with MMSE score(P<0.05), and 25(OH)D level was positively correlated with MMSE score in AD group(P<0.05). The results of multiple linear regression analysis showed that serum levels of 25(OH)D and SOST were the independent influencing factors of MMSE score in the AD patients. Conclusions Serum SOST level and 25(OH)D level are closely related to cognitive impairment in the AD patients, and can be potential therapeutic targets for AD.

Key words: sclerostin, 25 hydroxyvitamin D, Alzheimer's disease, mini-mental state examination